Orange Book product · Generic (ANDA)
MOMETASONE FUROATE
MOMETASONE FUROATE
At a glance
Mar 18, 2024
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Mar 18, 2024
2 yr 3 mo ago
Today
Pharmaceutical detail
Active ingredient
MOMETASONE FUROATE
Strength
0.05MG/SPRAY
Dosage form
SPRAY, METERED
Route
NASAL
TE code
AB
Application
ANDA 215878
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of MOMETASONE FUROATE
- 2022NASONEX 24HR ALLERGYBrand (NDA)
NDA 215712 · PERRIGO PHARMA INTL
- 2019ASMANEX HFABrand (NDA)
NDA 205641 · ORGANON LLC
- 2017SINUVABrand (NDA)
NDA 209310 · INTERSECT ENT INC
- 2008ASMANEX TWISTHALERBrand (NDA)
NDA 021067 · ORGANON LLC
- 1997NASONEXBrand (NDA)
NDA 020762 · ORGANON LLC
- 1989ELOCONBrand (NDA)
NDA 019796 · ORGANON
- 1987ELOCONBrand (NDA)
NDA 019625 · ORGANON
- 1987ELOCONBrand (NDA)
NDA 019543 · ORGANON
- 2025MOMETASONE FUROATEGeneric (ANDA)
ANDA 211706 · NASPRESS
- 2024MOMETASONE FUROATEGeneric (ANDA)
ANDA 217498 · AUROBINDO PHARMA
- 2024MOMETASONE FUROATEGeneric (ANDA)
ANDA 217438 · APOTEX
- 2023MOMETASONE FUROATEGeneric (ANDA)
ANDA 217460 · AMNEAL
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
